ICG-001
- ICG001;ICG 001
货号: abs810420
货号-规格 | 货期 | 价格 | 数量 |
abs810420-5mg | 1-2周 | ¥857.00 | - + |
abs810420-10mg | 现货 | ¥1541.00 | - + |
abs810420-50mg | 现货 | ¥4744.00 | - + |
abs810420-100mg | 现货 | ¥7610.00 | - + |

产品描述 | ||
描述 | ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro | |
纯度 | >98% | |
储存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. | |
基本信息 | ||
别名 | ICG001;ICG 001 | |
外观 | Off-white powder | |
可溶性/溶解性 | DMSO :100 mg/mL (182.27 mM) Ethanol :10 mg/mL (18.22 mM) | |
生物活性 | ||
靶点 | Wnt/β-catenin | |
In vitro(体外研究) | PRI-724 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with β-catenin. Treatment with PRI-724 selectively induces apoptosis in colon carcinoma cells but not in normal colonic epithelial cells and reduces in vitro growth of colon carcinoma cells. | |
In vivo(体内研究) | PRI-724 exhibits antitumor activity in the mouse xenograft models of colon cancer. The initial results of the Phase I clinic trial of PRI-724 has been disclosed publically. The drug exhibits an acceptable toxicity profile with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. An Open-Label dose-escalation phase I/II study of PRI-724 for patients with advanced myeloid malignancies is still ongoing. | |
温馨提示:本产品仅作科研实验使用,不支持临床等研究 |
- 实验方法 实验条件
共 0张,还能上传 8张 提交
- 提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
提交不成功?请联系info@absin.cn。
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。